Anti-VEGF Therapy Versus Dexamethasone Implant for DME
Status:
Not yet recruiting
Trial end date:
2023-06-24
Target enrollment:
Participant gender:
Summary
We look at a randomized comparative study of 2 FDA approved anti-VEGF agents(aflibercept and
ranibizumab) and see how they compare against the dexamethasone implant for phakic as well as
pseudophakic eyes with treatment naive diabetic macular edema in terms of efficacy and safety
over two years.